BiologicalDrug
Hizentra clinical trials
Also written IgPro20.
- studies test it
- 16
- open now
- 3
- in phase 3
- 10
- first study started
- 2006
Keep track of what changes. Save the Hizentra studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
16 studies that test it; most in 2008 (2)
| Year | Studies |
|---|---|
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 2 |
| 2010 | 1 |
| 2012 | 1 |
| 2014 | 2 |
| 2015 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2024 | 2 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 2
- 4
- Phase 3
- 10
- Phase 4
- 2
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 10 · Other 6
CSL Behring (10) · University of Alberta (1) · Mazen Dimachkie, MD (1) · Rochester General Hospital (1) · Memorial Sloan Kettering Cancer Center (1) · University of Alabama at Birmingham (1) · University of South Florida (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses Hizentra is read from its arms, and is right about nine times in ten.
Testing it · 16
- Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting TherapiesRecruitingPhase 3CSL BehringNCT07648264Written as IgPro20
- Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and HypogammaglobulinemiaRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT06976476Written as IgPro20
- Usage of Spirometry in Managing IgG Therapy in CVID With Airway DiseaseRecruitingPhase 4University of Alabama at BirminghamNCT05193552Written as Hizentra
- Double-blind, Randomized, Placebo-controlled Study Evaluating Efficacy and Safety of IgPro20 in Post-COVID-19 POTSTerminatedPhase 3CSL BehringNCT06524739Written as IgPro20
- Safety and Pharmacokinetics of IgPro20 and IgPro10 in Adults With Systemic Sclerosis (SSc)CompletedPhase 2CSL BehringNCT04137224Written as IgPro20
- A Pilot Trial To Assess The Feasibility And Efficacy Of SCIG In Patients With MG Exacerbation (SCIG-MG)CompletedPhase 3University of AlbertaNCT02774239Written as Human normal immunoglobulin G (IgG)
- Open Label Study of Subcutaneous Immunoglobulin (SCIg) in Myasthenia GravisCompletedPhase 2Mazen Dimachkie, MDNCT02100969Written as HIZENTRA ®
- Humoral Immunodeficiency in CLL and Therapy With Subcutaneous IgCompletedPhase 2/3Rochester General HospitalNCT03730129Written as Hizentra
- Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra) in Subjects With Primary Immunodeficiency (PID)CompletedPhase 4CSL BehringNCT03033745Written as IgPro20
- Extension Study of Maintenance Treatment With Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)CompletedPhase 3CSL BehringNCT02027701Written as IgPro20
- Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)CompletedPhase 3CSL BehringNCT01545076Written as IgPro20 (low dose)
- Extension Study of Subcutaneous Immunoglobulin Human in Patients With Primary Immunodeficiency (PID)CompletedPhase 3CSL BehringNCT00719680Written as IgPro20
- Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (EU Extension Study)CompletedPhase 3CSL BehringNCT00751621Written as IgPro20
- Study of Subcutaneous Immunoglobulin in Patients With PID Requiring IgG Replacement TherapyCompletedPhase 3CSL BehringNCT00419341Written as Human Normal Immunoglobulin for Subcutaneous Administration
- Evaluation of Efficacy and Tolerability of Hizentra®Status unknownNot applicableUniversity of South FloridaNCT01354587Written as Hizentra
- Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement TherapyCompletedPhase 3CSL BehringNCT00542997Written as Human Normal Immunoglobulin for Subcutaneous Administration (IGSC)